Health Canada Investigates Plasma Donor Deaths at Winnipeg Centres
Health Canada is currently investigating the deaths of two plasma donors at centers operated by Spanish pharmaceutical company Grifols in Winnipeg. These incidents have raised significant concerns regarding the safety of paid plasma donations in Canada.
Details of the Deaths
The federal oversight body was notified of the fatalities on October 25, 2025, and January 30, 2026. The deceased include a 22-year-old international student named Rodiyat Alabede, who had come to Canada from Nigeria to study at the University of Winnipeg. Health Canada refers to these incidents as “fatal adverse reactions,” but has not established a direct link between the donation process and the deaths.
Locations of the Incidents
- Grifols plasma center on Taylor Avenue
- Grifols plasma center on Innovation Drive
Grifols has expressed its condolences to the families of the deceased. The company announced it is conducting its own investigation and collaborating with Health Canada.
Response from Health Authorities
Canadian Blood Services (CBS), which oversees blood collection across most of Canada, indicated that it is unaware of any additional deaths linked to plasma donations. With the safety of the plasma donation process in question, the public is left waiting for further clarifications.
Existing Legal Issues
In addition to these tragic events, Grifols is facing a lawsuit related to a separate incident. Craig Loney, a 43-year-old aircraft maintenance technician, claims he suffered an acute kidney injury during a plasma donation at the Taylor Avenue center. In his lawsuit, Loney asserts that he received a notification about a machine error that harmed his health after the donation.
The Business of Plasma Donation in Canada
Grifols operates the only for-profit plasma collection centers in Canada. Since its acquisition of Canadian Plasma Resources Corporation in 2023, the company runs 17 sites across the country.
Controversy Over Paid Donations
Grifols compensates donors between $30 and $100, which has sparked debate. Critics argue that this payment structure may incentivize high-frequency donations that could compromise donor health and attract financially vulnerable individuals. Conversely, supporters argue that paid donations are essential for maintaining an adequate supply of plasma.
Regulatory Challenges
While paid plasma donations are banned in Ontario, British Columbia, and Quebec, Grifols operates in Ontario due to its partnership with CBS. Notably, a substantial portion of plasma collected in Canada is reportedly used to manufacture products for international markets.
Future Oversight
Members of Parliament on the House of Commons health committee have called for Grifols representatives to testify concerning Canada’s pharmaceutical sovereignty and the implications of exporting Canadian-donated plasma products.
As investigations continue, both Health Canada and the public remain focused on ensuring the safety and ethical practices surrounding plasma donations in Canada.
